You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Patent: 10,071,139


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,071,139
Title:Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
Abstract: Methods and compositions for reducing one or more of triglyceride levels, total cholesterol levels and LDL cholesterol levels in a subject are provided. The methods include administering a fragment of ANGPTL8 to a subject having or at risk of developing elevated triglyceride levels, elevated total cholesterol levels and/or elevated LDL cholesterol levels.
Inventor(s): Liu; Zhonghao (San Bruno, CA), Ding; Xunshan (San Bruno, CA)
Assignee: NGM Biopharmaceuticals, Inc. (South San Francisco, CA)
Application Number:15/318,937
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,071,139

Introduction

Patent 10,071,139, though not specifically detailed in the provided sources, can be analyzed within the broader context of the U.S. patent system, particularly focusing on recent changes, litigation trends, and the role of various entities in patent assertion. This analysis will delve into key factors influencing patent litigation, the impact of the Leahy-Smith America Invents Act (AIA), and the behaviors of different patent assertion entities.

The Leahy-Smith America Invents Act (AIA) and Its Impact

The AIA, enacted in 2011, is a pivotal piece of legislation that has significantly altered the U.S. patent landscape. It transformed the patent system from a first-to-invent to a first-inventor-to-file system, which has had profound implications for patent priority and litigation[2][3].

First-Inventor-To-File System

Under the AIA, the first person to file a patent application now has priority, even if another inventor can establish an earlier invention date. This change has streamlined the process but also introduced new complexities, such as the elimination of interference proceedings[2].

Creation of the Patent Trial and Appeal Board (PTAB)

The AIA established the PTAB, a tribunal within the U.S. Patent and Trademark Office (USPTO), to hear administrative challenges to the validity of patents. This includes inter partes review (IPR) and other post-grant review procedures. The PTAB has been seen as a mechanism to reduce unwarranted litigation costs and to weed out poor-quality patents, which can fuel litigation by non-practicing entities (NPEs)[3].

Patent Litigation Trends

Recent years have seen a notable increase in patent infringement lawsuits, particularly influenced by several key factors.

Unclear Property Rights

Many patents, especially those related to software, have overly broad or unclear claims. This ambiguity can lead to a higher likelihood of litigation as different parties may interpret the claims differently[1].

Monetary Incentives

The potential for large monetary awards from courts can incentivize patent owners to file infringement lawsuits, even for ideas that make only small contributions to a product[1].

Recognition of Patent Value

Companies have increasingly recognized the value of patents as strategic assets, leading to more aggressive patent assertion and litigation[1].

Role of Non-Practicing Entities (NPEs)

NPEs, often referred to as "patent trolls," play a significant role in patent litigation.

Business Models of NPEs

The Federal Trade Commission (FTC) has identified two main business models for NPEs: Litigation PAEs and Portfolio PAEs. Litigation PAEs primarily generate revenue through lawsuits, while Portfolio PAEs negotiate licenses for large portfolios of patents without necessarily resorting to litigation. Despite their smaller number, Portfolio PAEs generate a significant portion of the revenue from patent assertion activities[4].

Impact on Litigation

NPEs are involved in a substantial fraction of all patent lawsuits in the United States. The FTC study found that Litigation PAEs accounted for 91% of reported licenses, with patent infringement suits preceding most of these licenses. This highlights the litigious nature of many NPE activities[4].

Software-Related Patents

Software-related patents have been a major contributor to the increase in patent litigation.

Prevalence in Litigation

Software-related patents accounted for about 89% of the increase in defendants in patent infringement lawsuits from 2007 to 2011. These patents often have unclear or overly broad claims, which can lead to more frequent litigation[1].

Technological Categories

The FTC study noted that more than 75% of the patents held by PAEs were software-related, and these patents were asserted against firms in a broad range of industries, including retail trade[4].

Improving Patent Quality

Efforts to improve patent quality are crucial in reducing unnecessary litigation.

Linking Litigation Data to Patent Examination

The Government Accountability Office (GAO) recommended that the USPTO link trends in patent infringement litigation to internal data on the patent examination process to enhance patent quality. This approach could help identify and address issues with patent claims before they lead to litigation[1].

Guidelines for Patent Examiners

The USPTO has issued guidelines for patent examiners to determine whether a patent application seeks to claim ineligible subject matter, such as laws of nature, natural phenomena, or abstract ideas. These guidelines aim to ensure that only inventions with an "inventive concept" are patented[3].

Case Studies and Judicial Decisions

Recent judicial decisions and case studies provide insights into the complexities of patent litigation.

SNIPR Technologies Limited v. Rockefeller University

This case highlights the challenges under the first-inventor-to-file system and the role of the PTAB in resolving priority disputes. The decision underscores the importance of timely filing and the consequences of failing to assert an earlier invention date[2].

Key Takeaways

  • AIA Impact: The Leahy-Smith America Invents Act has significantly changed the U.S. patent system, introducing a first-inventor-to-file system and establishing the PTAB.
  • Litigation Trends: Unclear property rights, monetary incentives, and the recognition of patent value contribute to increased patent litigation.
  • NPEs: Non-practicing entities play a substantial role in patent litigation, with distinct business models such as Litigation PAEs and Portfolio PAEs.
  • Software Patents: Software-related patents are a major factor in patent litigation due to their often unclear or overly broad claims.
  • Improving Patent Quality: Linking litigation data to patent examination and adhering to guidelines for patent examiners are crucial for enhancing patent quality.

FAQs

What is the main difference between the pre-AIA and post-AIA patent systems?

The main difference is the shift from a first-to-invent to a first-inventor-to-file system, where the first person to file a patent application now has priority.

How has the PTAB impacted patent litigation?

The PTAB has provided a mechanism for challenging the validity of patents, which can reduce unwarranted litigation costs and weed out poor-quality patents.

What are the two main business models of Non-Practicing Entities (NPEs)?

The two main models are Litigation PAEs, which generate revenue primarily through lawsuits, and Portfolio PAEs, which negotiate licenses for large portfolios of patents.

Why are software-related patents more prone to litigation?

Software-related patents often have unclear or overly broad claims, which can lead to more frequent litigation.

How can patent quality be improved?

By linking trends in patent infringement litigation to internal data on the patent examination process and adhering to guidelines for determining eligible subject matter.

Sources

  1. GAO Report: Assessing Factors That Affect Patent Infringement Litigation.
  2. CAFC Opinion: SNIPR TECHNOLOGIES LIMITED v. ROCKEFELLER UNIVERSITY.
  3. CRS Report: The Patent Trial and Appeal Board and Inter Partes Review.
  4. FTC Study: Patent Assertion Entity Activity: An FTC Study.

More… ↓

⤷  Subscribe

Details for Patent 10,071,139

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 October 21, 1942 10,071,139 2034-10-03
Takeda Pharmaceuticals U.s.a., Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 March 03, 1954 10,071,139 2034-10-03
Csl Behring Ag ALBURX albumin (human) Injection 102366 July 23, 1976 10,071,139 2034-10-03
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 August 15, 1978 10,071,139 2034-10-03
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 November 29, 2022 10,071,139 2034-10-03
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 February 17, 1995 10,071,139 2034-10-03
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 June 11, 2003 10,071,139 2034-10-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.